alzheon.comHealthcare / BioTech & PharmaFounded: 2013Funding to Date: $189.27MM
Alzheon is a biopharmaceutical company striving to develop treatments designed for patients with Alzheimer’s Disease and other neurodegenerative disorders. Alzheon was founded in 2013 and is headquartered in Framingham, MA. Their leading candidate, ALZ-801, is an oral anti-amyloid treatment aimed at slowing or preventing Alzheimer’s disease, particularly in patients with specific genetic markers.
Funding Date | Share Class | Amount Raised | Price per Share | Post-Money Valuation | Key Investors | |
---|---|---|---|---|---|---|
06/12/2024 | Series E | $100MM | $xx.xx | $1.25B | Alerce Medical Technology Partners | |
Price per Share
$xx.xx
Shares Outstanding
1,594,642
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.7x
Dividend Rate
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
N/A
Key Investors
Alerce Medical Technology Partners
|
||||||
04/14/2022 | Series D | $50MM | $xx.xx | $516.92MM | Undisclosed Investors | |
Price per Share
$xx.xx
Shares Outstanding
1,388,889
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
N/A
Key Investors
Undisclosed Investors
|
||||||
04/25/2019 | Series C | $7.22MM | $xx.xx | $290.68MM | Undisclosed Investors | |
Price per Share
$xx.xx
Shares Outstanding
359,767
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
N/A
Key Investors
Undisclosed Investors
|
||||||
05/25/2017 | Series B | $20.85MM | $xx.xx | $164.91MM | Undisclosed Investors | |
Price per Share
$xx.xx
Shares Outstanding
4,622,227
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
0.4x
Dividend Rate
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
N/A
Key Investors
Undisclosed Investors
|
||||||
04/08/2015 | Series A | $11.2MM | $xx.xx | $37.33MM | Ally Bridge Group | |
Price per Share
$xx.xx
Shares Outstanding
8,175,303
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
0.4x
Dividend Rate
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
N/A
Key Investors
Ally Bridge Group
|